ZA200100294B - Coadministration of ACAT and MMP inhibitors for the treatment of atherosclerotic lesions. - Google Patents

Coadministration of ACAT and MMP inhibitors for the treatment of atherosclerotic lesions. Download PDF

Info

Publication number
ZA200100294B
ZA200100294B ZA200100294A ZA200100294A ZA200100294B ZA 200100294 B ZA200100294 B ZA 200100294B ZA 200100294 A ZA200100294 A ZA 200100294A ZA 200100294 A ZA200100294 A ZA 200100294A ZA 200100294 B ZA200100294 B ZA 200100294B
Authority
ZA
South Africa
Prior art keywords
acid
methyl
phenyl
biphenyl
hydroxy
Prior art date
Application number
ZA200100294A
Other languages
English (en)
Inventor
Thomas Michael Andrew Bocan
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of ZA200100294B publication Critical patent/ZA200100294B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Furan Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
ZA200100294A 1998-07-21 2001-01-10 Coadministration of ACAT and MMP inhibitors for the treatment of atherosclerotic lesions. ZA200100294B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9363998P 1998-07-21 1998-07-21

Publications (1)

Publication Number Publication Date
ZA200100294B true ZA200100294B (en) 2002-01-10

Family

ID=22239992

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200100294A ZA200100294B (en) 1998-07-21 2001-01-10 Coadministration of ACAT and MMP inhibitors for the treatment of atherosclerotic lesions.

Country Status (25)

Country Link
EP (1) EP1098662A2 (cs)
JP (1) JP2002521328A (cs)
KR (1) KR20010083134A (cs)
CN (1) CN1310629A (cs)
AP (1) AP2001002035A0 (cs)
AU (1) AU4701799A (cs)
BG (1) BG105162A (cs)
BR (1) BR9912296A (cs)
CA (1) CA2335062A1 (cs)
CZ (1) CZ2001126A3 (cs)
EA (1) EA200100153A1 (cs)
EE (1) EE200100046A (cs)
HR (1) HRP20010055A2 (cs)
HU (1) HUP0102880A3 (cs)
ID (1) ID30030A (cs)
IL (1) IL140982A0 (cs)
IS (1) IS5809A (cs)
NO (1) NO20010291D0 (cs)
OA (1) OA11584A (cs)
PL (1) PL346011A1 (cs)
SK (1) SK502001A3 (cs)
TR (1) TR200100205T2 (cs)
WO (1) WO2000004892A2 (cs)
YU (1) YU3501A (cs)
ZA (1) ZA200100294B (cs)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1210401A (en) * 1999-11-05 2001-06-06 Warner-Lambert Company Prevention of plaque rupture by acat inhibitors
CO5261615A1 (es) 1999-12-01 2003-03-31 Agouron Pharma Compuestos, composiciones y metodos para estimular el crecimiento y elongacion de neuronas
JP2003534239A (ja) * 1999-12-17 2003-11-18 ヴァージコア・インコーポレーテッド 新規なスクシナート化合物、組成物、並びに使用及び調製方法
NZ524406A (en) * 2000-09-01 2004-06-25 Sankyo Co Medicinal compositions containing HMG-CoA reductase inhibitor and ACAT inhibitor
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
BR0308908A (pt) * 2002-04-03 2005-01-04 Topotarget Uk Ltd Composto, composição, uso de um composto, e, métodos para inibir a hdac em uma célula, para o tratamento de uma condição mediada pela hdac, de um condição proliferativa, de câncer e de psorìase
CA2492035A1 (en) * 2002-07-11 2004-01-15 Vicuron Pharmaceuticals, Inc. N-hydroxyamide derivatives possessing antibacterial activity
WO2011092284A1 (en) * 2010-01-29 2011-08-04 Euroscreen S.A. Novel amino acid derivatives and their use as gpr43 receptor modulators
CN104211695B (zh) * 2013-06-04 2017-04-12 中国医学科学院医药生物技术研究所 一组胺甲酰基苯磺酰类化合物的用途
US20180000817A1 (en) * 2015-01-15 2018-01-04 Biocant - Associação De Transferência De Tecnologia Treatment of hutchinson-gilford progeria syndrome and diseases related to vascular ageing
CN106831697B (zh) * 2017-03-15 2019-11-05 深圳市康道生物有限公司 川榛有效提取成分及其在防治动脉粥样硬化中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366987A (en) * 1991-08-22 1994-11-22 Warner-Lambert Company Isoxazolyl-substituted alkyl amide ACAT inhibitors
US5491172A (en) * 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
CA2221729A1 (en) * 1995-08-04 1997-02-20 Warner-Lambert Company Use of sulfamic acid derivatives, acyl sulfonamides or sulfonyl carbamates for the manufacture of a medicament for lowering lipoprotein levels
DE69707865T2 (de) * 1996-05-17 2002-05-02 Warner-Lambert Co., Morris Plains Biphenylsulfonamid matrix metalloproteinase inhibitoren
BR9711988A (pt) * 1996-09-04 1999-08-24 Warner Lambert Co Inibidores de metaloproteinase de matriz e seus empregos terap-uticos

Also Published As

Publication number Publication date
OA11584A (en) 2004-07-20
CA2335062A1 (en) 2000-02-03
JP2002521328A (ja) 2002-07-16
BG105162A (en) 2001-12-29
CZ2001126A3 (cs) 2002-01-16
HUP0102880A2 (en) 2002-06-29
KR20010083134A (ko) 2001-08-31
ID30030A (id) 2001-11-01
HRP20010055A2 (en) 2002-04-30
EA200100153A1 (ru) 2001-08-27
IL140982A0 (en) 2002-02-10
AU4701799A (en) 2000-02-14
IS5809A (is) 2001-01-12
WO2000004892A2 (en) 2000-02-03
PL346011A1 (en) 2002-01-14
NO20010291L (no) 2001-01-18
WO2000004892A3 (en) 2000-05-18
EP1098662A2 (en) 2001-05-16
CN1310629A (zh) 2001-08-29
HUP0102880A3 (en) 2002-11-28
SK502001A3 (en) 2002-06-04
TR200100205T2 (tr) 2001-05-21
AP2001002035A0 (en) 2001-03-31
NO20010291D0 (no) 2001-01-18
BR9912296A (pt) 2001-04-17
YU3501A (sh) 2005-06-10
EE200100046A (et) 2002-06-17

Similar Documents

Publication Publication Date Title
AU741768B2 (en) Method for treating and preventing heart failure and ventricular dilatation
AU737117B2 (en) Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing
AU751701B2 (en) Ace inhibitor-MMP inhibitor combinations
ZA200100294B (en) Coadministration of ACAT and MMP inhibitors for the treatment of atherosclerotic lesions.
ZA200106780B (en) Aromatic sulfone hydroxamic acid metalloprotease inhibitor.
US5629343A (en) N-(mercaptoacyl) peptidyl derivatives as antidegenerative agents
KR20010041916A (ko) 스타틴-매트릭스 메탈로프로테이나제 저해제 복합제제
MXPA01000780A (en) Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions
MXPA02007736A (es) Agente de tratamiento para osteoartritis.
US20050020607A1 (en) Statin-MMP inhibitor combinations
EP1366765A1 (en) Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing
HK1038317A (en) Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions
MXPA99002254A (en) Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing
AU2003248291A1 (en) Statin-matrix metalloproteinase inhibitor combinations